<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">DOLASETRON MESYLATE</span><br/>(dol-a-se'tron)<br/><span class="topboxtradename">Anzemet<br/></span><b>Classifications:</b> <span class="classification">gastrointestinal agent</span>; <span class="classification">antiemetic</span>; <span class="classification">5-ht<sub>3</sub> antagonist</span><br/><b>Prototype: </b>Ondansetron<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>50 mg, 100 mg tablets; 20 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Dolasetron is a selective serotonin (5-HT<sub>3</sub>) receptor antagonist used for control of nausea and vomiting associated with cancer chemotherapy. Serotonin receptors affected
         by dolasetron are located in the chemoreceptor trigger zone (CTZ) of the brain and peripherally on the vagal nerve terminal.
         Serotonin, released from the cells of the small intestine, activate 5-HT<sub>3</sub> receptors located on vagal efferent, neurons, thus initiating the vomiting reflex. Dolasetron causes ECG changes lasting
         from 6 to 24 h.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>This selective serotonin (5-HT<sub>3</sub>) receptor antagonist has antiemetic properties that help patients on chemotherapy.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Prevention of nausea and vomiting from emetogenic chemotherapy, prevention and treatment of postoperative nausea and vomiting.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to dolasetron.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Patients who have or may develop prolongation of cardiac conduction intervals, particularly QT<sub>c</sub> (i.e., patients with hypokalemia, hypomagnesia, diuretics, congenital QT syndrome; patients taking antiarrhythmic drugs and
         high-dose anthracycline therapy, etc.), pregnancy (category B), and lactation. Safety and efficacy in children 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Prevention of Chemotherapy-induced Nausea and Vomiting</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 1.8 mg/kg or 100 mg administered over 30 s, 30 min prior to chemotherapy <span class="rdroute">PO</span> 100 mg 1 h prior to chemotherapy<br/><span class="rdage">Child:</span> <span class="rdroute">IV</span> &gt;<i>2 y</i>, 1.8 mg/kg or 100 mg administered over 30 s, 30 min prior to chemotherapy <span class="rdroute">PO</span> &gt;<i>2 y</i>, 1.8 mg/kg up to 100 mg 1 h before chemotherapy<br/><br/><span class="indicationtitle">Pre/Postoperative Nausea and Vomiting</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 12.5 mg 15 min before cessation of anesthesia or when post-op nausea and vomiting occurs <span class="rdroute">PO</span> 100 mg within 2 h prior to surgery<br/><span class="rdage">Child:</span> <span class="rdroute">IV</span> &gt;<i>2 y</i>, 0.35 mg/kg up to 12.5 mg 15 min before cessation of anesthesia or when post-op nausea and vomiting occurs <span class="rdroute">PO</span> &gt;<i>2 y</i>, 1.2 mg/kg up to 100 mg starting 2 h prior to surgery (may also mix IV formulation in apple or apple-grape juice and administer
               orally)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give dissolved in apple or apple-grape juice 1 h before chemotherapy.</li>
<li>Give within 2 h before surgery, when used for post-op nausea.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Give undiluted.  <span class="methodtype">IV Infusion:</span> Dilute in 50 mL of any of the following: NS, D5W, D5/0.45% NaCl, LR.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Inject undiluted drug over 30 s.  <span class="methodtype">IV Infusion:</span> Infuse diluted drug over 15 min.  
               </p>
</td>
</tr>
</table>
<ul>
<li>Store at 20°25° C (66°77° F) and protect from light.</li>
<li>Diluted IV solution may be stored refrigerated up to 48 h.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Fever, fatigue, pain, chills or shivering. <span class="typehead">CNS:</span> <span class="speceff-common">Headache,</span> dizziness, drowsiness. <span class="typehead"> CV:</span> Hypertension. <span class="typehead">GI:</span> <span class="speceff-common">Diarrhea,</span> increased LFTs, abdominal pain. <span class="typehead">Genitourinary:</span> Urinary retention. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed from GI tract, converted to hydrodolasetron, the active metabolite. <span class="typehead">Peak:</span> 0.6 h IV, 1 h PO. <span class="typehead">Distribution:</span> Crosses placenta, distributed into breast milk. <span class="typehead">Metabolism:</span> Metabolized to hydrodolasetron by carbonyl reductase. Hydrodolasetron is metabolized in the liver by CYP2D6. <span class="typehead">Elimination:</span> Primarily excreted in urine as unchanged hydrodolasetron. <span class="typehead">Half-Life:</span> 10 min dolasetron, 7.3 h hydrodolasetron. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Therapeutic effectiveness: Prevention of nausea and vomiting.</li>
<li>Determine serum electrolytes before initiating drug. Hypokalemia and hypomagnesemia should be correct before initiating therapy.</li>
<li>Monitor closely cardiac status especially with vomiting, excess diuresis, or other conditions that may result in electrolyte
            imbalances.
         </li>
<li>Monitor ECG, especially in those taking concurrent antiarrhythmic or other drugs that may cause QT prolongation.</li>
<li>Monitor for and report signs of bleeding (e.g., hematuria, epistaxis, purpura, hematoma).</li>
<li>Lab tests: With prolonged therapy, periodically monitor liver functions, PTT, CBC with platelet count, and alkaline phosphatase.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Headache requiring analgesic for relief is a common adverse effect.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>